alternatives to glp-1 weight loss medications What's New in Obesity Treatment? The Boom in New Weight

and the staff at the Biophysics Platform, Protein Structure and Function Program from The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen for performing the human serum albumin SPR binding measurements

The biochemistry is real

Exploring tirzepatide mechanisms in detail provides additional context

The people I see in clinic, they care about getting out of a chair, playing with their grandchildren, not being admitted into a nursing home, Batsis says

Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index

In the CNS, GLP-1s may impact neuronal function in conditions, such as Alzheimer's disease and Parkinson's disease, through multiple mechanisms